Cryo-Cell International Inc
AMEX:CCEL
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.3
9.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cryo-Cell International Inc
Capital Expenditures
Cryo-Cell International Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cryo-Cell International Inc
AMEX:CCEL
|
Capital Expenditures
-$4.1m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
-34%
|
|
|
DaVita Inc
NYSE:DVA
|
Capital Expenditures
-$543.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Capital Expenditures
-$374m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
CVS Health Corp
NYSE:CVS
|
Capital Expenditures
-$2.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Cigna Corp
NYSE:CI
|
Capital Expenditures
-$1.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-12%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Capital Expenditures
-$545m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
Cryo-Cell International Inc
Glance View
Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation services and advancing regenerative medicine. The company is headquartered in Oldsmar, Florida and currently employs 83 full-time employees. The firm operates through three segments: The cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family use; the manufacture of PrepaCyte CB units, the processing technology used to process umbilical cord blood stem cells, and the cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives and other related healthcare professionals. The Company, in combination with its global affiliates, stores approximately 500,000 cord blood and cord tissue specimens around the world for the benefit of newborn babies and possibly other members of their families. Its processing and storage of specimens is handled from its facility in Oldsmar, Florida.
See Also
What is Cryo-Cell International Inc's Capital Expenditures?
Capital Expenditures
-4.1m
USD
Based on the financial report for Aug 31, 2024, Cryo-Cell International Inc's Capital Expenditures amounts to -4.1m USD.
What is Cryo-Cell International Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-34%
Over the last year, the Capital Expenditures growth was 19%. The average annual Capital Expenditures growth rates for Cryo-Cell International Inc have been -37% over the past three years , -50% over the past five years , and -34% over the past ten years .
You don't have any saved screeners yet
